OBI Pharma, Inc
OBI Pharma is a global clinical stage oncology company dedicated to developing innovative cancer therapies, including antibody-drug conjugates (ADCs) and active immunotherapies. With a focus on unmet medical needs, the company advances next-generation technologies and collaborates globally to bring first-in-class and best-in-class drugs to market, aiming to improve patient outcomes and quality of life.
Industries
Products
Clinical-stage ADC therapeutic candidates (multiple targets)
A portfolio of clinical and preclinical ADC candidates targeting tumor antigens (including TROP2, Nectin4, HER2 and dual-antigen formats) developed using site-specific conjugation and linker technologies.
Enzyme-activated prodrug candidates
Prodrug molecules designed to be activated by tumor-associated enzymes to selectively release cytotoxic agents within cancer cells.
Clinical-stage ADC therapeutic candidates (multiple targets)
A portfolio of clinical and preclinical ADC candidates targeting tumor antigens (including TROP2, Nectin4, HER2 and dual-antigen formats) developed using site-specific conjugation and linker technologies.
Enzyme-activated prodrug candidates
Prodrug molecules designed to be activated by tumor-associated enzymes to selectively release cytotoxic agents within cancer cells.
Services
Platform licensing and technology transfer for ADC enabling technologies
Licensing and transferring enabling ADC technologies and know-how to partners, including master services and marketing agreements to expand regional adoption of conjugation and glycan production capabilities.
Clinical development and regulatory submissions
Execution of multi-phase clinical programs and preparation of regulatory filings (IND/CTA) to advance oncology candidates through clinical development.
Out-licensing and commercialization support
Out-licensing of therapeutic candidates and support for commercialization strategies including market partnerships and transfer of product rights to affiliates or partners.
Platform licensing and technology transfer for ADC enabling technologies
Licensing and transferring enabling ADC technologies and know-how to partners, including master services and marketing agreements to expand regional adoption of conjugation and glycan production capabilities.
Clinical development and regulatory submissions
Execution of multi-phase clinical programs and preparation of regulatory filings (IND/CTA) to advance oncology candidates through clinical development.
Out-licensing and commercialization support
Out-licensing of therapeutic candidates and support for commercialization strategies including market partnerships and transfer of product rights to affiliates or partners.
Expertise Areas
- Antibody-drug conjugate development
- Glycoscience and glycan engineering
- Linker and conjugation chemistry
- Bispecific and multi‑payload ADC engineering
Key Technologies
- Glycan-based site-specific conjugation
- Cysteine-selective conjugation chemistry
- Hydrophilic linker chemistry
- Endoglycosidase-mediated transglycosylation